US dermatology market analysis 2026 — 13,774 practice locations, California leads at 12.6% share, Salt Lake City the highest-density metro
The 2026 Ichelon Consulting US Dallas view of the US dermatology practice market — how the 13,774 practice-location base is distributed by state, why California and Salt Lake City sit at opposite ends of the density map, how medical, surgical and cosmetic sub-mixes decide margin per location, and the acquisition math a growing practice actually needs to run.
- The US dermatology practice base is approximately 13,774 locations in 2026, aggregating AAD directory listings, ASDS membership registries and WebMD provider counts. The base includes general medical dermatology, surgical/Mohs practices and cosmetic-heavy locations.
- California leads the state map with 1,743 practice locations — 12.6% of the national base. New York, Texas, Florida and Pennsylvania complete the top five. Sun-belt demography plus cosmetic-services demand drives concentration.
- Salt Lake City is the highest-density derma metro among US metros over 1M population, at approximately 4.96 practices per 100,000 residents. Boston, San Francisco, Miami and New York follow.
- Cosmetic dermatology has grown to roughly one-third of practice-level revenue across a mixed panel of practices. Adjacent US medical aesthetics market: $9.46B (2026) → $17.45B by 2031 at 13% CAGR (MarketsAndMarkets).
- Cost-per-qualified-lead in 2026 ranges from USD 55-220 for general dermatology, USD 90-320 for Mohs/surgical, and USD 75-260 for cosmetic dermatology. Cost-per-booked-consultation is 2x-3.5x the CPQL.
- The compliance stack is federal (HIPAA, TCPA, CAN-SPAM, ADA, FTC 16 CFR §255, FDA 21 CFR §202.1) plus state medical board rules. Every practice growth plan must clear both layers.
- Dallas, Texas LLC
- 10-person US client team · Central Time (CST)
- 25+ US healthcare clients
- BAA signed with every client
- HIPAA compliance training across client and delivery teams
- Contracts and invoices in USD
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“They were able to get all my ideas and work with me over a period of three to four months and create this amazing website. It's super customized, very modern, and it incorporates all the elements that I had wanted — the patient portal, nice pictures, a very interactive website, patient reviews. I would highly recommend their company to anyone who wants to make an excellent website.”
Sizing the US dermatology practice base at 13,774 locations
Sizing a US dermatology practice base to a single number is harder than sizing a medspa base. There is no single national directory, and the boundary between a “derma practice location” and an adjacent aesthetic clinic, plastic-surgery practice with a cosmetic dermatology line, or hospital-employed dermatology department is fuzzy. The 13,774 figure is the practical operational aggregate: American Academy of Dermatology (AAD) directory listings de-duped against ASDS (American Society for Dermatologic Surgery) membership rolls and the WebMD provider-count file, filtered to distinct practice locations rather than distinct providers.
The right number for a market planner is 13,774. The right number for a workforce planner is different because a single practice location can host 3-8 providers, and the physician-productivity dilution factor across a location varies materially between metro and micropolitan geographies.
The base is not evenly distributed across the derma sub-mix. Of the 13,774 locations, general medical dermatology remains the majority category, Mohs and surgical dermatology forms a specialist minority anchored around board-certified Mohs surgeons, and cosmetic-heavy practices form a rapidly growing minority in the sun-belt metros and coastal-city corridors.
Why the count matters for a growth plan
The count matters because it defines the competitive intensity of any given metro. A metro at 2 practices per 100,000 residents is meaningfully under-served and rewards a well-run local search plan disproportionately. A metro at 5+ practices per 100,000 — the Salt Lake City band — requires differentiation, niche positioning and referral-network work to grow.
State-by-state US dermatology practice distribution
California leads the state distribution with approximately 1,743 practice locations, or 12.6% of the national base. That is a share materially larger than California’s share of US population, driven by a combination of an aesthetic-heavy consumer base, a large cosmetic-adjacent physician workforce, and metro clusters (Los Angeles, San Francisco, San Diego, Sacramento) each with strong independent and consolidated derma platforms.
New York, Texas, Florida and Pennsylvania complete the top five. The pattern here reflects age demographics as much as absolute population — states with a higher-than-average share of residents over 55 tend to over-index on derma practice base because both medical dermatology (skin-cancer screening, actinic keratosis, and chronic dermatoses) and cosmetic dermatology (age-related aesthetic work) both scale with that population band.
| Rank | State | Approx. derma practice locations (2026) | National share | Leading metros |
|---|---|---|---|---|
| 1 | California | ~1,743 | 12.6% | Los Angeles, San Francisco, San Diego, Sacramento |
| 2 | New York | ~1,050 (est.) | ~7.6% | New York City, Long Island, Westchester, Hudson Valley |
| 3 | Texas | ~950 (est.) | ~6.9% | Dallas-Fort Worth, Houston, Austin, San Antonio |
| 4 | Florida | ~920 (est.) | ~6.7% | Miami, Tampa, Orlando, Jacksonville |
| 5 | Pennsylvania | ~620 (est.) | ~4.5% | Philadelphia, Pittsburgh, Allentown |
| 6 | Illinois | ~560 (est.) | ~4.1% | Chicago, North Shore, Naperville |
| 7 | Ohio | ~460 (est.) | ~3.3% | Columbus, Cleveland, Cincinnati |
| 8 | Massachusetts | ~430 (est.) | ~3.1% | Boston, Cambridge, Worcester |
| 9 | Georgia | ~410 (est.) | ~3.0% | Atlanta metro, Athens, Savannah |
| 10 | New Jersey | ~390 (est.) | ~2.8% | Bergen County, Northern NJ, Central NJ |
Why California over-indexes so heavily
California’s 12.6% share reflects three compounding factors: high absolute population, high concentration of aesthetically-attuned professional consumers with private-pay purchasing power, and a comparatively mature cosmetic-derma workforce anchored by USC, UCLA, Stanford and UC San Diego training pipelines. The state also has a well-developed private-equity-consolidated derma platform layer, which pulls forward location build-out relative to states with a more purely independent practice base.
The sun-belt second wave
Texas, Florida, Georgia and Arizona together represent the second-wave growth zone. All four states are gaining net domestic migration in the professional bands that drive both medical and cosmetic derma demand, and all four have advertising and delegation frameworks that permit meaningful cosmetic-derma expansion. Every practice planning a multi-state growth strategy should be looking at this second wave.
Highest-density US derma metros — Salt Lake City tops the 1M+ list
Metro-level density is a better competitive indicator than state-level count. Salt Lake City is the highest-density dermatology metro among US metros over 1 million population, at approximately 4.96 practices per 100,000 residents. That density is a compound of a strong University of Utah medical dermatology base plus an unusually deep aesthetic base for a metro of its size.
Boston, San Francisco, Miami and New York City are next-tier density metros in the 1M+ bracket. Manhattan alone runs at a density well above the metro average, similar to the Manhattan medspa concentration.
| Metro (1M+ pop.) | Density · practices per 100k | Notable dynamics |
|---|---|---|
| Salt Lake City | ~4.96 | Highest density metro over 1M · University of Utah medical anchor + aesthetic depth |
| Boston | ~4.2 (est.) | Harvard, BU, Tufts training pipelines; established medical + cosmetic mix |
| San Francisco | ~4.0 (est.) | UCSF, Stanford anchors; high-ticket cosmetic base |
| Miami | ~3.8 (est.) | Per-capita aesthetic capital; strong international referrer base |
| New York City (metro) | ~3.5 (est.) | Manhattan much higher; boroughs lower |
| Los Angeles | ~3.3 (est.) | Coastal density; Inland Empire under-served relative to metro |
| Philadelphia | ~3.0 (est.) | UPenn, Jefferson, Temple pipelines; mature independent base |
| Denver | ~2.8 (est.) | Rising cosmetic base with strong medical dermatology footprint |
| Atlanta | ~2.7 (est.) | Growing cosmetic base + medical dermatology solid |
| Dallas-Fort Worth | ~2.6 (est.) | Fastest-growing density profile in top ten |
What high density means for a growth plan
High density does not mean the metro is closed to a new practice. It means the growth plan has to be built around differentiation — a specific sub-specialty (Mohs, pediatric, complex medical dermatology, or a specific cosmetic device franchise), a specific consumer segment, a specific insurance-network position, or a specific physical-location advantage. A generic “we do everything” positioning does not win in a 4-per-100k metro.
The correct diagnostic before a metro-entry plan is a density-and-position analysis, not a generic media-planning exercise.
Medical, surgical and cosmetic sub-mix — where the practice-level margin lives
US dermatology practice-level revenue in 2026 is split across three broad sub-mixes: medical dermatology (skin-cancer screening, chronic dermatoses, biologic therapies, general medical work), surgical and Mohs dermatology (skin-cancer excision, reconstructive surgery, complex procedures), and cosmetic dermatology (neuromodulators, dermal fillers, laser, energy-based devices, chemical peels, cosmeceutical retail).
Margin per hour of physician time varies substantially across the three sub-mixes. Medical dermatology is the volume base — consistent, insurance-reimbursed, moderate margin. Mohs is high-margin per case but requires specific board certification and a specialized support workforce. Cosmetic is the highest gross margin per hour on a straight private-pay basis and has been the fastest-growing sub-mix over the past decade.
| Sub-mix | Approx. share of practice revenue (mixed panel) | Typical margin profile | Growth trajectory |
|---|---|---|---|
| General medical dermatology | ~50-60% | Insurance-reimbursed · consistent moderate margin | Stable · grows with population aging |
| Surgical & Mohs dermatology | ~10-20% | High margin per case · specialty-limited workforce | Steady growth · skin-cancer incidence rising |
| Cosmetic dermatology | ~25-35% | Highest gross margin · private-pay | Fastest-growing sub-mix · ~13% CAGR adjacent |
| Retail & ancillary | ~3-8% | Retail-margin cosmeceuticals | Modest growth · membership-anchored |
The cosmetic-mix expansion pattern
The single most common growth pattern in a US dermatology practice through 2026 is the deliberate expansion of the cosmetic sub-mix from ~15% of revenue to 25-35% inside 24 months. The mechanics are consistent: a dedicated cosmetic-derma page cluster on the practice website, a physician-reviewed cosmetic treatment library, a dedicated cosmetic-derma injector on the schedule, a rebuilt price ladder that separates cosmetic from medical, and a marketing plan that separates the cosmetic funnel from the medical one.
Where medical-only practices should not force cosmetic
A general medical dermatology practice built around insurance-referral flow and biologic-therapy management should not automatically pivot toward cosmetic. The transformation cost is real (workflow, staff training, capital), the compliance envelope is different, and the marketing skill-set is different. Some medical-only practices are better off doubling down on differentiated medical work — complex psoriasis biologics, atopic dermatitis, dermato-oncology follow-up — where the referring-physician network drives the volume.
US dermatology CPQL, CPBC and referrer economics in 2026
Dermatology acquisition math is meaningfully different from medspa acquisition math. Medical dermatology relies heavily on primary-care referrer flow and insurance network positioning, which does not show up as a paid-media CPQL but does dominate the practical new-patient economics. Cosmetic dermatology runs on a paid-media plus reputational-referral model that looks closer to medspa economics. Mohs dermatology is a referring-dermatologist and MOHs-registry model with a distinctive path.
| Sub-vertical | CPQL band (2026) | CPBC band (2026) | Primary demand-gen path |
|---|---|---|---|
| General medical dermatology (new patient) | $55 – $220 | $130 – $520 | Local SEO + GBP + primary-care referrer network |
| Cosmetic dermatology · injectables | $65 – $220 | $180 – $600 | Google Search + Meta Ads + reviews + membership |
| Cosmetic dermatology · laser/energy | $85 – $260 | $220 – $700 | Search + retargeting + treatment-page content depth |
| Surgical / Mohs dermatology | $90 – $320 | $260 – $860 | Referring dermatologist network + physician content + registry positioning |
| Pediatric dermatology | $70 – $240 | $180 – $580 | Pediatric referrer network + parent-facing content |
| Skin-cancer screening (self-referred) | $60 – $210 | $150 – $520 | Local SEO + community content + insurance-listed profile |
Why the referrer network is still the biggest input
For a medical dermatology practice, the largest single input to new-patient economics is not paid media — it is the strength and specific composition of the primary-care and specialty-referrer network. A practice that receives 60% of new patients from primary-care and internal-medicine referrers is running a fundamentally different economics than a practice that runs a paid-media-dominant new-patient flow.
The correct integration for a growth plan is a referrer-network development track alongside the paid-media track. The two feed each other — a strong physician-content library helps referrers refer with confidence, and a well-optimized paid-media plan captures the self-referred half of the funnel without cannibalizing the referrer flow.
Cosmetic derma vs. medspa acquisition — the substitutable but not identical question
Cosmetic dermatology and medspa cosmetic services overlap on treatment menu but not on positioning. A cosmetic dermatology practice trades on the board-certified dermatologist credential and physician-led delivery. A medspa trades on convenience, price point and consumer-brand experience. The paid-media plans that work for each are similar in mechanics but different in creative, price point and consult protocol. Trying to run a medspa creative playbook on a cosmetic dermatology account produces reliably worse economics than a dermatology-native playbook.
Private-equity consolidation and its effect on the independent practice
The US dermatology consolidation cycle has meaningfully reshaped the practice base since 2018. Multi-state dermatology platforms — the group of ten to twelve PE-backed and operator-led networks that have rolled up practices across California, Texas, Florida, New York and multiple sun-belt states — now hold a substantial minority share of the practice base in high-density metros. In markets like Dallas-Fort Worth, Atlanta and Phoenix, the consolidated platform layer is a real competitive factor.
What the consolidated layer does well: procurement, group purchasing on drugs and devices, centralized marketing spend at bulk-rate CPMs, and a workforce pipeline for non-physician providers. What it typically does not do well: local reputational depth, deep referring-physician relationships built over decades, and community-embedded trust. That gap is where independent practices sustain a real competitive advantage.
HIPAA, state medical boards and derma advertising rules
US dermatology practices are HIPAA covered entities the moment they transmit any health information electronically in connection with a HIPAA transaction — which in 2026 is essentially every US derma practice. That means the Privacy Rule marketing provisions at 45 CFR 164.501 apply, and the Office for Civil Rights tracking-technology guidance updated in March 2024 applies.
The three highest-risk surfaces on a derma practice website
Consistent with the medspa pattern, the three highest-risk tracking surfaces on a dermatology practice website are: the patient portal (any tag is PHI-adjacent because the user is authenticated), the appointment-booking flow (provider and specialty plus IP is a PHI disclosure when forwarded to a non-BAA vendor), and the condition-specific pages (a “psoriasis” page or a “skin cancer” page with an IP-carrying pixel forwarded to a non-BAA vendor is exactly the pattern OCR called out in the 2024 update).
The fix is a server-side tagging container inside the practice’s BAA-covered perimeter, with field-level allow-listing, URL rewriting for condition-specific pages, and consent-mode enforcement in every downstream vendor request.
State medical board overlays worth knowing
California Business & Professions Code §651 sets a strict false-and-misleading standard that catches many superlatives (“best,” “leading”) that would pass in other states. Texas Medical Board Chapter 164 has specific rules on before/after and testimonials. Florida Board of Medicine imposes disclosure rules on cosmetic claims. New York Public Health Law §238 governs fee disclosure and testimonials. Georgia and Arizona have specific advertising rules that intersect with cosmetic-derma marketing directly.
The practical implication is that a national derma platform running identical creative across all 50 states is running compliance risk in at least three of them. State-scoped creative variants and a claim-substantiation binder are table stakes.
Three US derma patient segments that shape the growth plan
Segment 1 · The medical patient
Referred or self-referred for a specific medical dermatology need (screening, acne, psoriasis, eczema, complex work). Insurance-driven; loyal to the practice while the specific need persists; converts to cosmetic 12-25% of the time if the medical experience is excellent.
Segment 2 · The cosmetic maintenance patient
Age 35-60, private-pay, quarterly to twice-annual cadence, LTV of USD 3,400-8,600 over three years. Trades physician credential over convenience; retention is a function of consult experience and predictable results.
Segment 3 · The high-ticket surgical patient
Mohs excision, reconstructive surgery, or complex cosmetic surgical procedure. Deliberates for weeks; needs physician credentialing depth, procedure content, referring-physician endorsement. Once converted, becomes a strong referral generator.
The seven levers that actually move a US dermatology practice in 2026
- Lever 1 · Physician-authored content depth. A dermatology practice with 40+ physician-reviewed condition and procedure pages consistently outperforms one with a shallow brochure site by a factor of 3-5x in organic new-patient volume.
- Lever 2 · Referring-physician network development. A quarterly referrer touch-point program — educational content, brief in-person or virtual roundtables, referring-physician-specific case updates — moves referral volume more than any paid-media dollar in a medical-heavy practice.
- Lever 3 · Google Business Profile discipline (Angryturtle). Weekly GBP posts, review responses tied to reviewer name, Q&A moderated for HIPAA, category and attribute optimization. This is the highest-ROI hour of the week in a derma practice.
- Lever 4 · Cosmetic sub-mix build-out. A dedicated cosmetic-derma page cluster, a dedicated cosmetic injector or physician, a rebuilt price ladder, a Meta Ads plan built around Segment 2. Moves cosmetic revenue share from ~15% to 25-35% inside 24 months.
- Lever 5 · Insurance-network position and transparency. Clear insurance acceptance display, verified insurance plan lists, and specific accepted-plan pages. Reduces call-center friction and lifts organic conversion.
- Lever 6 · Named-physician byline on every treatment page. Person schema, biography, credential list, published work, media appearances. E-E-A-T signal for organic ranking and compliance defensibility for FTC and state board reviews.
- Lever 7 · AI Overview capture layer. Deep FAQ pages, speakable-marked H2s, MedicalCondition and MedicalProcedure schema. Positions the practice for the AIO citation share that increasingly precedes traditional organic click.
The US derma practice base at Ichelon Consulting US
Ichelon Consulting US operates from Dallas, TX — inside the third-largest state on the US derma map — and serves independent and multi-location dermatology practices across California, New York, Texas, Florida, Pennsylvania, Illinois, Ohio, Massachusetts, Georgia and New Jersey. Every engagement is HIPAA-scoped, state medical board-vetted, and CPQL-benchmarked against the ranges published in this report.
Backed by ICG global leadership
Every US dermatology engagement has direct line-of-sight to the Ichelon Consulting US Leadership Team, with senior reviewers who have scaled US dermatology accounts through the current consolidation cycle and the 2024 OCR tracking-technology transition.
Our own tools run inside every engagement
Ichelon Consulting US uses software built by our own product team. Practices can also use most tools on their own, billed in USD.
US dermatology market — common questions
How many dermatology practices are there in the United States in 2026?
Approximately 13,774 practice locations, aggregating AAD directory, ASDS membership and WebMD provider counts, de-duped to distinct practice locations.
Which US state has the most dermatology practices?
California leads with approximately 1,743 practice locations, or 12.6% of the national base. New York, Texas, Florida and Pennsylvania complete the top five.
Which US metro has the highest dermatology practice density?
Salt Lake City — approximately 4.96 practices per 100,000 residents, the highest among metros over 1M population. Boston, San Francisco, Miami and NYC follow.
What treatment mix drives US dermatology revenue in 2026?
Medical dermatology (~50-60%), cosmetic dermatology (~25-35%), surgical/Mohs (~10-20%), retail/ancillary (~3-8%). Cosmetic has been the fastest-growing sub-mix.
What is the typical cost-per-qualified-lead for a US dermatology practice?
USD 55-220 general dermatology, USD 90-320 Mohs/surgical, USD 75-260 cosmetic dermatology (blended 2026 US media). Wider in NYC, LA, Miami; tighter in secondary metros.
What compliance rules govern US dermatology marketing?
Federal: HIPAA, TCPA, CAN-SPAM, ADA, FTC 16 CFR §255, FDA 21 CFR §202.1. State: medical board and, where applicable, physician assistant and nursing board rules.
How does dermatology private-equity consolidation affect independent practices?
Consolidated platforms hold a substantial minority share of practices in high-density metros. Independents win on named-physician content, referring-physician relationships and local review depth.
How large is the adjacent US medical aesthetics market?
USD 9.46 billion in 2026, projected USD 17.45 billion by 2031 at 13% CAGR (MarketsAndMarkets). Cosmetic dermatology practices sit at the higher-margin end of this adjacent market.
What sub-specialty positioning wins in a high-density metro?
Complex medical dermatology (biologics, dermato-oncology follow-up, atopic dermatitis), Mohs, pediatric, or a specific cosmetic device franchise. Generic “everything” positioning does not win.
What is the fastest way to grow the cosmetic sub-mix in a medical-heavy practice?
Dedicated cosmetic page cluster, dedicated cosmetic injector or physician, rebuilt price ladder, separate paid-media funnel, and a membership program. 24-month expansion from ~15% to 25-35% is a typical target.
Scope a US derma practice growth engagement
Book a 30-minute call with a member of the Leadership Team, email the US practice lead in Dallas, or reach us by phone. Retainers are custom-scoped per engagement · from USD 1,800/month equivalent for foundational SEO + GBP OS.
Continue the US aesthetic stack
Healthcare brands ICG
has worked with.
A representative slice of the 150+ healthcare brands ICG has delivered for across India. Full client list available under NDA during a Brand and Growth Diagnostic.
Key findings
- The US dermatology practice base is approximately 13,774 locations in 2026.
- California leads with 1,743 practice locations, 12.6% of the national base, followed by New York, Texas, Florida and Pennsylvania.
- Salt Lake City is the highest-density dermatology metro over 1M population, at about 4.96 practices per 100,000 residents.
- Cosmetic dermatology has grown to roughly one-third of practice-level revenue across a mixed panel of practices.
- Every growth plan must clear both federal rules (HIPAA, TCPA, CAN-SPAM, ADA, FTC and FDA advertising rules) and state medical board rules.
How to cite this report
US Dermatology Market Analysis 2026, Ichelon Consulting Group, 2026. https://ichelonconsulting.com/us-dermatology-market-analysis-2026
Free to quote and reuse with attribution and a link to this page.
Related research
Questions this report answers
How many dermatology practices are there in the US?
About 13,774 practice locations in 2026, according to Ichelon Consulting US's market analysis, which aggregates professional directory listings and membership registries. The base includes medical, surgical and Mohs, and cosmetic-heavy locations.
Which state has the most dermatology practices?
California, with 1,743 locations, or 12.6% of the national base. New York, Texas, Florida and Pennsylvania complete the top five, driven by Sun Belt demographics and cosmetic demand, according to the 2026 analysis.
Which US city has the most dermatologists per capita?
Salt Lake City, at about 4.96 practices per 100,000 residents among metros over 1M population. Boston, San Francisco, Miami and New York follow in the analysis. The base covers about 13,774 practice locations nationwide in 2026.
How much of a dermatology practice's revenue is cosmetic?
Roughly one-third across the mixed panel of practices in the analysis. The report treats the medical, surgical and cosmetic sub-mix as the main driver of margin per location. The analysis covers about 13,774 US practice locations in 2026.